DrugPatentWatch Database Preview
AMYVID Drug Profile
When do Amyvid patents expire, and when can generic versions of Amyvid launch?
Amyvid is a drug marketed by Avid Radiopharms Inc and is included in one NDA. There are two patents protecting this drug.
This drug has forty-six patent family members in thirty-one countries.
The generic ingredient in AMYVID is florbetapir f-18. One supplier is listed for this compound. Additional details are available on the florbetapir f-18 profile page.
Summary for AMYVID
| International Patents: | 46 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 3 |
| Clinical Trials: | 35 |
| DailyMed Link: | AMYVID at DailyMed |
Generic Entry Opportunity Date for AMYVID
Generic Entry Date for AMYVID*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for AMYVID
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Elisa Konofagou | N/A |
| National Institute on Aging (NIA) | N/A |
| University of California, Irvine | Phase 3 |
Pharmacology for AMYVID
| Drug Class | Radioactive Diagnostic Agent |
| Mechanism of Action | Positron Emitting Activity |
Synonyms for AMYVID
| [18F]Florbetapir |
| 18F-AV-45 |
| 18F-AV45 |
| 18FAV45 |
| 4-((1E)-2-(6-{2-(2-(2-(18F)fluoroethoxy)ethoxy)ethoxy}pyridin-3-yl)ethenyl)-N- methylbenzenamine |
| 4-(2-(6-(2-(2-(2-Fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methylbenzamide |
| 4-[(E)-2-[6-(2-{2-[2-(18F)fluoroethoxy]ethoxy}ethoxy)pyridin-3-yl]ethenyl]-N-methylaniline |
| 4-{(E)-2-[6-(2-{2-[2-((18)F)fluoroethoxy]ethoxy}ethoxy)pyridin-3-yl]ethenyl}-N-methylaniline |
| 4-{(E)-2-[6-(2-{2-[2-(18F)fluoroethoxy]ethoxy}ethoxy)pyridin-3-yl]ethenyl}-N-methylaniline |
| 6W15Z5R0RU |
| 956103-76-7 |
| Amyvid (TN) |
| AV-45 |
| AV-45 compound |
| Benzenamine, 4-((1E)-2-(6-(2-(2-(2-(fluoro-18F)ethoxy)ethoxy)ethoxy)-3- pyridinyl)ethenyl)-N- methyl- |
| CHEBI:66880 |
| CHEMBL1774461 |
| D09617 |
| DB09149 |
| DTXSID80241898 |
| Florbetapir |
| florbetapir (18F) |
| Florbetapir (18F) [INN] |
| Florbetapir F 18 |
| Florbetapir F-18 |
| Florbetapir F-18 (USAN) |
| Florbetapir F-18 [USAN:INN] |
| florbetapir F18 |
| florbetapir-fluorine-18 |
| GTPL7344 |
| Pet AV-45 |
| SCHEMBL14826096 |
| UNII-6W15Z5R0RU |
| YNDIAUKFXKEXSV-CRYLGTRXSA-N |
US Patents and Regulatory Information for AMYVID
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Avid Radiopharms Inc | AMYVID | florbetapir f-18 | SOLUTION;INTRAVENOUS | 202008-001 | Apr 6, 2012 | DISCN | No | No | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Avid Radiopharms Inc | AMYVID | florbetapir f-18 | SOLUTION;INTRAVENOUS | 202008-002 | Apr 6, 2012 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Avid Radiopharms Inc | AMYVID | florbetapir f-18 | SOLUTION;INTRAVENOUS | 202008-001 | Apr 6, 2012 | DISCN | No | No | Start Trial | Start Trial | Y | Y | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for AMYVID
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Cyprus | 1113048 | Start Trial |
| Portugal | 2363392 | Start Trial |
| Portugal | 1999109 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for AMYVID
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1999109 | 34/2013 | Austria | Start Trial | PRODUCT NAME: FLORBETAPIR (18F); REGISTRATION NO/DATE: EU/1/12/805 20130114 |
| 1999109 | 2013/028 | Ireland | Start Trial | PRODUCT NAME: FLORBETAPIR (18F), OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALT; REGISTRATION NO/DATE: EU/1/12/805 20130114 |
| 1999109 | 13C0034 | France | Start Trial | PRODUCT NAME: FLORBETAPIR (18F); REGISTRATION NO/DATE: EU/1/12/805 20130114 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
